Enliven Therapeutics, Inc. research snapshot
ELVN AI stock analysis currently reads Enliven Therapeutics as a clinical-stage biopharmaceutical company with a precision oncology pipeline led by ELVN-001, a highly selective ATP-competitive BCR-ABL inhibitor for chronic myeloid leukemia (CML). At the July 12, 2026 data cutoff, ELVN closed near $51.09 on July 10, with a verified market capitalization of about $3.11 billion based on 60.9 million shares outstanding. The stock is rallying near its 52-week high after positive updated Phase 1 ENABLE data presented at the June 2026 European Hematology Association Congress and FDA alignment on key Phase 3 trial design components. The company holds approximately $452.4 million in cash with minimal debt, 95% institutional ownership, 14.4% short interest, and a strong scientific advisory board including Brian Druker (Gleevec pioneer). The bear case focuses on binary regulatory outcomes, a single lead asset, high short interest, insider selling after the rally, and the lack of any approved product revenue. This page is informational only and not investment advice.
Current price
$51.09
Market cap
$3.11 billion verified market cap
AI score
50 / 100
Rating
Speculative clinical-stage biotech with strong Phase 1 CML data and binary pipeline risk
Trend status
Strong uptrend, near 52-week high, event-driven after positive Phase 1 ENABLE data and FDA alignment for Phase 3
Data cutoff (updated weekly)
July 12, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Enliven Therapeutics is a pre-revenue clinical-stage biopharmaceutical company with one lead asset (ELVN-001 for CML) showing positive Phase 1 data and FDA alignment for Phase 3. The business quality cannot be assessed on revenue or profit because no product is approved yet. | Low |
| Moat | The potential moat depends on ELVN-001 IP protection, regulatory exclusivity, differentiation from existing CML TKIs (including asciminib), manufacturing scale, and commercial adoption. The narrow selectivity profile and unique P-loop binding mode could provide a competitive advantage if Phase 3 confirms the Phase 1 results. | Low-medium |
| Management | CEO Rick Fair brings 25+ years of pharma experience including senior roles at Roche/Genentech and J&J. Co-founders (Kintz, Lyssikatos, Patel) have strong scientific and operational credentials from AbbVie, Genentech, and Biogen. CMO Helen Collins was CMO at Five Prime Therapeutics. The key unknown is ability to execute a Phase 3 pivotal trial and build commercial infrastructure. | Medium |
| Financial trend | ELVN has no revenue, a trailing net loss of approximately $99 million (TTM), cash of $452.4 million, and minimal debt. The recent upsized public offering added capital but also diluted existing shareholders. Cash runway supports Phase 3 initiation but must be monitored vs burn rate. | Medium |
| Valuation | At $51.09 and $3.11B market cap, ELVN trades entirely on ELVN-001 probability-adjusted value. Traditional P/E is not applicable. Price/Book of 6.60x is high but not extreme for pre-revenue biotechs with positive late-stage clinical data. Valuation depends on Phase 3 success probability, CML market size, pricing, and commercial execution. | Low |
| Technical trend | Strong uptrend with the stock up approximately 232% year-to-date and trading near its 52-week high of $52.39. The stock is event-driven and can gap significantly on clinical, regulatory, or financing news. | Medium |
| Risk level | Risk is very high. Pre-revenue biotech with binary Phase 3 outcome, 14.4% short interest, insider selling after the rally, single-asset pipeline concentration risk (ELVN-002 is being re-evaluated), potential dilution, and high volatility. | High |
| AI confidence | Descriptive research on clinical data, cash position, management, and analyst targets is reasonably supported. Any forecast of future stock prices has very low confidence because a single clinical readout, regulatory decision, or financing event can dominate all other factors. | Low |
| Investment certainty | Investment certainty is very low for a pre-revenue biotech with one lead clinical asset, regardless of the quality of Phase 1 data. Position sizing should reflect the high probability of capital loss if ELVN-001 fails in Phase 3 or faces regulatory delays. | Very low |
ELVN AI stock forecast
The ELVN AI stock forecast uses scenario ranges rather than a precise price prediction. Traditional valuation tools are not meaningful because ELVN has no revenue or positive earnings. The forecast depends on ELVN-001 Phase 3 progress, potential partnership or licensing events, competition in the CML market (especially asciminib from Novartis), and the binary nature of clinical-stage biotech investing.
$75 to $95
More likely if ELVN-001 Phase 3 data confirms strong efficacy and safety, the company secures a partnership with a larger pharmaceutical company for ex-US commercialization, ELVN-001 demonstrates superiority or meaningful differentiation vs asciminib and other TKIs, and the cash runway extends through key catalysts without dilutive financing.
$40 to $60
More likely if the stock trades around current expectations while the market waits for Phase 3 enrollment updates and interim data, pricing reflects normal biotech volatility between binary events, and the company proceeds with the planned ENABLE-2 Phase 3 trial initiation in H2 2026.
$15 to $30
More likely if ELVN-001 Phase 3 data disappoints on efficacy or safety, regulatory timelines slip, competitive pressure from asciminib or other TKIs increases, the company requires dilutive financing at unfavorable terms, or ELVN-002 strategic alternatives do not produce value.
ELVN AI technical analysis
ELVN AI technical analysis starts from the $51.09 July 10, 2026 close. The stock has a 52-week range of $14.78 to $52.39, with the YTD return of about 232%. Moving averages and momentum indicators should be confirmed in a live charting tool before use, as this static page does not fetch request-time data.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $51.09 | Close on July 10, 2026. The stock is trading near its 52-week high of $52.39. |
| Near support | $44 to $48 | Estimated from recent trading range during the June-July 2026 rally. A pullback to this zone would be a normal retracement in a strong uptrend. |
| Deeper support | $33 to $38 | This zone overlaps with the previous resistance-turned-support area from the pre-rally consolidation range near the 50-day moving average zone. |
| Near resistance | $52 to $53 | The current 52-week high is $52.39 (MarketBeat). A breakout above this level would signal continued momentum and open the path toward analyst target levels. |
| Upper resistance | $60 to $65 | This zone aligns with analyst price targets. Stifel initiated with a $60 target in June 2026. |
| Moving averages | Requires live chart confirmation | The stock has been in a strong uptrend since early 2026. The 50-day moving average is likely in the mid-$30s range based on the price range. Confirm before trading. |
| Momentum | Strong positive, event-driven | The stock gained about 232% YTD. Momentum is driven by clinical and regulatory catalysts rather than fundamental earnings growth. |
| Volume | Average volume near 2.18 million shares | Volume spiked significantly on Phase 1 data news in June 2026 and on the recent public offering. Watch for volume confirmation on breakouts. |
| Volatility | Very high | Pre-revenue biotech stocks regularly move 5-15% on clinical, regulatory, or financing news. ELVN has shown intraday ranges exceeding 10% on catalyst days. |
| Invalidation | Close below $44, then below $33 | A sustained break below $44 would weaken the short-term uptrend. A break below $33 would challenge the broader bullish thesis. |
ELVN AI trading strategy
The ELVN AI trading strategy is a rules-based framework for a speculative clinical-stage biotech stock. It is not personal advice and should be paired with live quotes, SEC filings, clinical trial calendars, FDA timelines, cash burn monitoring, and strict position sizing.
Consider ELVN only if it holds above the $44 to $48 near support zone and confirms an uptrend with volume. Enter on pullbacks to support rather than chasing breakouts above $52, given the high volatility and event-driven nature.
A close below $44 or a failed breakout above $52 with below-average volume should trigger a review. Clinical setbacks, regulatory delays, or dilutive financing would invalidate the trend thesis entirely.
If ELVN pulls back toward the $33 to $38 deeper support zone without negative clinical news, compare the price action with the next expected catalyst (Phase 3 enrollment initiation, data readouts) and the latest financial disclosures on cash runway.
Do not average down. Set a predefined maximum loss and honor it. Pre-revenue biotechs can decline 40-60% on bad data regardless of technical support levels.
Track the evidence that matters most for a CML-focused biotech: ELVN-001 Phase 3 (ENABLE-2) enrollment progress, safety updates, efficacy data, competitive landscape (asciminib, ponatinib, olverembatinib), cash runway, potential partnerships, and ELVN-002 strategic alternative outcomes.
Reduce exposure if Phase 3 timelines slip significantly, if safety concerns emerge from longer-term follow-up, if competitor data raises the bar for CML treatment, or if cash burn accelerates without clear clinical catalysts ahead.
Investment research summary
Enliven Therapeutics aims to develop best-in-class small molecule kinase inhibitors for cancer patients who need more efficacious, better-tolerated, and more convenient therapies than currently available. The lead candidate ELVN-001 targets CML with a uniquely selective ATP-competitive binding mode designed to avoid the off-target toxicity of existing TKIs.
The potential moat depends on ELVN-001 IP protection, regulatory exclusivity, and differentiation from the current standard-of-care CML TKIs including asciminib. The narrow selectivity profile and unique P-loop binding mode could provide a meaningful competitive advantage, but this is unproven until Phase 3 data confirms Phase 1 results at scale.
The thesis fails if ELVN-001 Phase 3 data does not match Phase 1 results, if asciminib or other competitors maintain or extend their CML market leadership, if regulatory requirements for Phase 3 are more demanding than expected, if the company runs out of cash before reaching approval, or if safety signals emerge in larger patient populations.
CEO Rick Fair brings deep pharma commercialization experience from Roche/Genentech and J&J. The co-founders have strong drug discovery backgrounds from AbbVie, Genentech, and Biogen. The board includes Brian Druker (Gleevec pioneer) as a scientific advisor, and Lori Kunkel (former CMO of Pharmacyclics, involved in Imbruvica approval). The key test is Phase 3 execution and potential commercial infrastructure buildout.
CML has been transformed by TKIs from a fatal disease to a manageable chronic condition, but patients still face resistance, intolerance, and quality-of-life barriers. The global opportunity for better-tolerated, more convenient CML therapies remains significant. The rise of asciminib and other allosteric inhibitors creates both competitive pressure and potential combination opportunities.
With no revenue and negative EPS, traditional valuation metrics do not provide a margin of safety. The current $3.11B market cap prices in a meaningful probability of ELVN-001 Phase 3 and commercial success. The margin of safety improves only with clear Phase 3 data, partnership validation, or demonstrated clinical superiority over existing CML therapies.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| Current price | $51.09 close on July 10, 2026 | MarketBeat ELVN quote | July 12, 2026 |
| Market capitalization | $3.11 billion, verified as $51.09 x 60.9M shares = $3.11B | Pineify financial_rigor.py calculation from MarketBeat | July 12, 2026 |
| Cash and equivalents | $452.4 million | Yahoo Finance key statistics | July 12, 2026 |
| Debt/Equity | 0.07% (minimal debt) | Yahoo Finance balance sheet | July 12, 2026 |
| Net income (TTM) | -$98.78 million | Yahoo Finance financials | July 12, 2026 |
| EPS (TTM) | -$1.67 | MarketBeat statistics | July 12, 2026 |
| Price/Book (mrq) | 6.60x | MarketBeat valuation data | July 12, 2026 |
| Levered FCF (TTM) | -$46.08 million | Yahoo Finance cash flow | July 12, 2026 |
| 52-week range | $14.78 to $52.39 | MarketBeat quote data | July 12, 2026 |
| Short interest | 14.43% of float | MarketBeat short interest | July 12, 2026 |
| Institutional ownership | 95.08% | MarketBeat ownership data | July 12, 2026 |
| Analyst consensus | Moderate Buy, average PT $69.17, range $59 to $80 | MarketBeat analyst forecast | July 12, 2026 |
| CEO | Rick Fair (CEO since 2023, 25+ years pharma) | Enliven Therapeutics leadership page | July 12, 2026 |
| Scientific advisor | Brian Druker, MD (Gleevec pioneer, OHSU Knight Cancer Institute) | Enliven Therapeutics scientific advisors | July 12, 2026 |
This ELVN AI stock analysis page is an informational research tool only. It is not investment advice, financial advice, a recommendation, or a guarantee of future returns. Forecast ranges are scenarios based on available public filings, quote snapshots, clinical data disclosures, and third-party sources as of July 12, 2026. They may be wrong, incomplete, or outdated after new clinical data, FDA decisions, financing events, competitive developments, or market moves. Clinical-stage biotech investments carry a very high risk of capital loss, and past stock price performance does not guarantee future results.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
